413 related articles for article (PubMed ID: 33615173)
1. Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial.
Cruz LR; Baladrón I; Rittoles A; Díaz PA; Valenzuela C; Santana R; Vázquez MM; García A; Chacón D; Thompson D; Perera G; González A; Reyes R; Torres L; Pérez J; Valido Y; Rodriguez R; Vázquez-Bloomquist DM; Rosales M; Ramón AC; Pérez GV; Guillén G; Muzio V; Perera Y; Perea SE;
ACS Pharmacol Transl Sci; 2021 Feb; 4(1):206-212. PubMed ID: 33615173
[TBL] [Abstract][Full Text] [Related]
2. Targeting CK2 mediated signaling to impair/tackle SARS-CoV-2 infection: a computational biology approach.
Miranda J; Bringas R; Fernandez-de-Cossio J; Perera-Negrin Y
Mol Med; 2021 Dec; 27(1):161. PubMed ID: 34930105
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
4. The synthetic peptide CIGB-300 modulates CK2-dependent signaling pathways affecting the survival and chemoresistance of non-small cell lung cancer cell lines.
Cirigliano SM; Díaz Bessone MI; Berardi DE; Flumian C; Bal de Kier Joffé ED; Perea SE; Farina HG; Todaro LB; Urtreger AJ
Cancer Cell Int; 2017; 17():42. PubMed ID: 28373828
[TBL] [Abstract][Full Text] [Related]
5. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
6. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
[TBL] [Abstract][Full Text] [Related]
7. Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300.
Rosales M; Pérez GV; Ramón AC; Cruz Y; Rodríguez-Ulloa A; Besada V; Ramos Y; Vázquez-Blomquist D; Caballero E; Aguilar D; González LJ; Zettl K; Wiśniewski JR; Yang K; Perera Y; Perea SE
Biomedicines; 2021 Jul; 9(7):. PubMed ID: 34356831
[TBL] [Abstract][Full Text] [Related]
8. CIGB-300, an anti-CK2 peptide, inhibits angiogenesis, tumor cell invasion and metastasis in lung cancer models.
Benavent Acero F; Capobianco CS; Garona J; Cirigliano SM; Perera Y; Urtreger AJ; Perea SE; Alonso DF; Farina HG
Lung Cancer; 2017 May; 107():14-21. PubMed ID: 27319334
[TBL] [Abstract][Full Text] [Related]
9. CIGB-300, a synthetic peptide-based drug that targets the CK2 phosphoaceptor domain. Translational and clinical research.
Perea SE; Baladron I; Garcia Y; Perera Y; Lopez A; Soriano JL; Batista N; Palau A; Hernández I; Farina H; Garcia I; Gonzalez L; Gil J; Rodriguez A; Solares M; Santana A; Cruz M; Lopez M; Valenzuela C; Reyes O; López-Saura PA; González CA; Diaz A; Castellanos L; Sanchez A; Betancourt L; Besada V; González LJ; Garay H; Gómez R; Gómez DE; Alonso DF; Perrin P; Renualt JY; Sigman H; Herrera L; Acevedo B
Mol Cell Biochem; 2011 Oct; 356(1-2):45-50. PubMed ID: 21735096
[TBL] [Abstract][Full Text] [Related]
10. Targeting of Protein Kinase CK2 Elicits Antiviral Activity on Bovine Coronavirus Infection.
Ramón AC; Pérez GV; Caballero E; Rosales M; Aguilar D; Vázquez-Blomquist D; Ramos Y; Rodríguez-Ulloa A; Falcón V; Rodríguez-Moltó MP; Yang K; Perera Y; Perea SE
Viruses; 2022 Mar; 14(3):. PubMed ID: 35336959
[TBL] [Abstract][Full Text] [Related]
11. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
12. CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo.
Perea SE; Reyes O; Baladron I; Perera Y; Farina H; Gil J; Rodriguez A; Bacardi D; Marcelo JL; Cosme K; Cruz M; Valenzuela C; López-Saura PA; Puchades Y; Serrano JM; Mendoza O; Castellanos L; Sanchez A; Betancourt L; Besada V; Silva R; López E; Falcón V; Hernández I; Solares M; Santana A; Díaz A; Ramos T; López C; Ariosa J; González LJ; Garay H; Gómez D; Gómez R; Alonso DF; Sigman H; Herrera L; Acevedo B
Mol Cell Biochem; 2008 Sep; 316(1-2):163-7. PubMed ID: 18575815
[TBL] [Abstract][Full Text] [Related]
13. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial.
Caballero Bermejo AF; Ruiz-Antorán B; Fernández Cruz A; Diago Sempere E; Callejas Díaz A; Múñez Rubio E; Avendaño-Solá C; Ramos Martínez A; Sancho López A;
Trials; 2020 Sep; 21(1):794. PubMed ID: 32938496
[TBL] [Abstract][Full Text] [Related]
14. Clinical-Grade Peptide-Based Inhibition of CK2 Blocks Viability and Proliferation of T-ALL Cells and Counteracts IL-7 Stimulation and Stromal Support.
Perera Y; Melão A; Ramón AC; Vázquez D; Ribeiro D; Perea SE; Barata JT
Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32471246
[TBL] [Abstract][Full Text] [Related]
15. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
[TBL] [Abstract][Full Text] [Related]
16. CIGB-300: A peptide-based drug that impairs the Protein Kinase CK2-mediated phosphorylation.
Perea SE; Baladrón I; Valenzuela C; Perera Y
Semin Oncol; 2018 Jan; 45(1-2):58-67. PubMed ID: 30318085
[TBL] [Abstract][Full Text] [Related]
17. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
Trials; 2021 May; 22(1):343. PubMed ID: 34001215
[TBL] [Abstract][Full Text] [Related]
18. CIGB-300 anticancer peptide regulates the protein kinase CK2-dependent phosphoproteome.
Perera Y; Ramos Y; Padrón G; Caballero E; Guirola O; Caligiuri LG; Lorenzo N; Gottardo F; Farina HG; Filhol O; Cochet C; Perea SE
Mol Cell Biochem; 2020 Jul; 470(1-2):63-75. PubMed ID: 32405972
[TBL] [Abstract][Full Text] [Related]
19. Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial.
Garcia PJ; Mundaca H; Ugarte-Gil C; Leon P; Malaga G; Chaccour C; Carcamo CP
Trials; 2021 Apr; 22(1):262. PubMed ID: 33836826
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS
Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
